Trust & Proof: Gilead Sciences (ZYDELIG) – Signal Evidence & AI Readability

{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://health-lifesci.schema.org/Patient",
    "specialty": "https://health-lifesci.schema.org/Oncologic",
    "url": "https://www.zydelig.com",
    "headline": "ZYDELIG® (idelalisib) | Relapsed CLL Treatment",
    "description": "Learn about treatment with ZYDELIG® (idelalisib), including financial information, side effect management, and helpful resources related to your treatment.",
    "mainContentOfPage": {
        "@type": "WebPageElement",
        "potentialAction": [
            {
                "@type": "Action",
                "name": "What is ZYDELIG?",
                "url": "https://www.zydelig.com/resources/about-zydelig"
            },
            {
                "@type": "Action",
                "name": "Addressing your side effects",
                "url": "https://www.zydelig.com/side-effects/tips-for-managing-reporting"
            },
            {
                "@type": "Action",
                "name": "Discover helpful resources",
                "url": "hhttps://www.zydelig.com/resources/patient-caregiver-resources"
            }
        ],
        "text": "What is ZYDELIG? ZYDELIG (idelalisib) is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL), in combination with Rituxan® (rituximab), when CLL comes back after prior cancer treatment and when Rituxan treatment alone may be used due to other health problems. ZYDELIG should not be used as the first medicine to treat anyone, including people with CLL, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), and other slow growing (indolent) non-Hodgkin lymphomas.ZYDELIG should not be used in combination with bendamustine and Rituxan, or in combination with Rituxan to treat people with FL, SLL, and other indolent non-Hodgkin lymphomas."
    },
    "about": [
        {
            "@type": "MedicalCondition",
            "name": [
                "Relapsed chronic lymphocytic leukemia (CLL)"
            ]
        },
        {
            "@type": "MedicalTherapy",
            "guideline": [
                "Adult starting dose: One 150 mg tablet twice daily, swallowed whole with or without food. Continue treatment until disease progression or unacceptable toxicity. The safe dosing regimen for patients who require treatment longer than several months is unknown.",
                "Dose modification: Consult the ZYDELIG full Prescribing Information for dose modification and monitoring recommendations for the following specific toxicities: pneumonitis, ALT/AST elevations, bilirubin elevations, diarrhea, neutropenia, thrombocytopenia, and infections. For other severe or life-threatening toxicities, withhold ZYDELIG until toxicity is resolved and reduce the dose to 100 mg twice daily upon resuming treatment. If severe or life-threatening toxicities recur upon rechallenge, ZYDELIG should be permanently discontinued.",
                "CYP3A inducers: Avoid coadministration with strong CYP3A inducers.",
                "CYP3A inhibitors: Avoid coadministration with strong CYP3A inhibitors. If unable to use alternative drugs, monitor patients more frequently for ZYDELIG adverse reactions.",
                "CYP3A substrates: Avoid coadministration with sensitive CYP3A substrates."
            ],
            "adverseOutcome": "The most common adverse reactions (incidence ≥20%) in patients treated with Zydelig in the monotherapy trial are diarrhea, fatigue nausea, cough, pyrexia, abdominal pain, pneumonia, and rash.The most common adverse reactions (incidence ≥30%) in patients treated with Zydelig in combination trials are diarrhea, pneumonia,pyrexia, fatigue, rash, cough, and nausea.Common laboratory abnormalities include neutropenia, ALT elevations and AST elevations.",
            "seriousAdverseOutcome": [
                "Severe cutaneous reactions: Monitor patients for the development of severe cutaneous reactions and discontinue Zydelig.",
                "Anaphylaxis: Monitor patients for anaphylaxis and discontinue Zydelig.",
                "Neutropenia: monitor blood counts."
            ],
            "contraindication": [
                "History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis"
            ],
            "recognizingAuthority": {
                "@type": "Organization",
                "name": "U.S. Food and Drug Administration",
                "alternateName": "FDA",
                "url": "https://www.fda.gov/"
            }
        },
        {
            "@type": "Drug",
            "name": "ZYDELIG®",
            "offers": {
                "@type": "Offer",
                "price": "0",
                "priceCurrency": "USD"
            },
            "activeIngredient": "idelalisib",
            "alternateName": "ZYDELIG® (idelalisib)",
            "dosageForm": "tablet",
            "administrationRoute": "oral",
            "doseSchedule": [
                {
                    "@type": "DoseSchedule",
                    "frequency": "twice-daily",
                    "doseUnit": [
                        "150 mg",
                        "100 mg"
                    ],
                    "targetPopulation": [
                        "adults",
                        "adults who have received at least two prior systemic therapies"
                    ]
                }
            ],
            "pregnancyWarning": "Embryo-fetal toxicity: Zydelig may cause fetal harm. Advise women of potential risk to a fetus and to avoid pregnancy while taking Zydelig.",
            "breastfeedingWarning": "Lactation: Advise women not to breastfeed",
            "warning": [
                "WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC,SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, and INTESTINAL PERFORATION See full prescribing information for complete boxed warning",
                "Fatal and/or serious hepatotoxicity occurred in 16% to 18% of Zydelig-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Zydelig.",
                "Fatal and/or serious and severe diarrhea or colitis occurred in 14% to 20% of Zydelig-treated patients. Monitor for the development of severe diarrhea or colitis. Interrupt and then reduce or discontinue Zydelig.",
                "Fatal and/or serious pneumonitis occurred in 4% of Zydeligtreated patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt or discontinue Zydelig",
                "Fatal and/or serious infections occurred in 21% to 48% of Zydelig-treated patients. Monitor for signs and symptoms of infection. Interrupt Zydelig if infection is suspected.",
                "Fatal and serious intestinal perforation can occur in Zydeligtreated patients across clinical trials. Discontinue Zydelig if intestinal perforation is suspected."
            ],
            "image": {
                "@type": "ImageObject",
                "name": "ZYDELIG®(idelalisib)logo",
                "contentUrl": "https://www.zydelig.com/Content/images/logo.png"
            },
            "manufacturer": {
                "@type": "Organization",
                "name": "Gilead",
                "logo": "https://www.zydelig.com/Content/images/GILEAD-logo.png"
            }
        }
    ]
}

[
    {
        "@context": "http://schema.org",
        "@type": "MedicalWebPage",
        "audience": "https://health-lifesci.schema.org/Clinician",
        "specialty": "https://health-lifesci.schema.org/Oncologic",
        "description": "ZYDELIG® (idelalisib) information for healthcare professionals. Learn how you may be able to help your patients with relapsed chronic lymphocytic leukemia (CLL).",
        "url": "https://www.zydelig.com/hcp",
        "headline": "ZYDELIG® (idelalisib) for Relapsed CLL | HCP Site",
        "mainContentOfPage": {
            "@type": "WebPageElement",
            "potentialAction": [
                {
                    "@type": "Action",
                    "name": "Zydelig efficacy",
                    "description": "View efficacy",
                    "url": "https://www.zydelig.com/hcp/efficacy"
                },
                {
                    "@type": "Action",
                    "name": "Zydelig safety profile",
                    "description": "View details",
                    "url": "https://www.zydelig.com/hcp/safety-profile"
                },
                {
                    "@type": "Action",
                    "name": "ZYDELIG® AccessConnect®",
                    "description": "Call to learn more 1-844-622-2377"
                },
                {
                    "@type": "Action",
                    "name": "Adverse event monitoring & management",
                    "description": "View details",
                    "url": "https://www.zydelig.com/hcp/adverse-event-management"
                },
                {
                    "@type": "Action",
                    "name": "Healthcare professional resources",
                    "description": "Get information",
                    "url": "https://www.zydelig.com/hcp/healthcare-professional-resources"
                }
            ]
        },
        "about": [
            {
                "@type": "MedicalCondition",
                "name": [
                    "Relapsed chronic lymphocytic leukemia (CLL)"
                ]
            },
            {
                "@type": "MedicalTherapy",
                "guideline": [
                    "Adult starting dose: One 150 mg tablet twice daily, swallowed whole with or without food. Continue treatment until disease progression or unacceptable toxicity. The safe dosing regimen for patients who require treatment longer than several months is unknown.",
                    "Dose modification: Consult the ZYDELIG full Prescribing Information for dose modification and monitoring recommendations for the following specific toxicities: pneumonitis, ALT/AST elevations, bilirubin elevations, diarrhea, neutropenia, thrombocytopenia, and infections. For other severe or life-threatening toxicities, withhold ZYDELIG until toxicity is resolved and reduce the dose to 100 mg twice daily upon resuming treatment. If severe or life-threatening toxicities recur upon rechallenge, ZYDELIG should be permanently discontinued.",
                    "CYP3A inducers: Avoid coadministration with strong CYP3A inducers.",
                    "CYP3A inhibitors: Avoid coadministration with strong CYP3A inhibitors. If unable to use alternative drugs, monitor patients more frequently for ZYDELIG adverse reactions.",
                    "CYP3A substrates: Avoid coadministration with sensitive CYP3A substrates."
                ],
                "adverseOutcome": "The most common adverse reactions (incidence ≥20%) in patients treated with Zydelig in the monotherapy trial are diarrhea, fatigue nausea, cough, pyrexia, abdominal pain, pneumonia, and rash.The most common adverse reactions (incidence ≥30%) in patients treated with Zydelig in combination trials are diarrhea, pneumonia,pyrexia, fatigue, rash, cough, and nausea.Common laboratory abnormalities include neutropenia, ALT elevations and AST elevations.",
                "seriousAdverseOutcome": [
                    "Severe cutaneous reactions: Monitor patients for the development of severe cutaneous reactions and discontinue Zydelig.",
                    "Anaphylaxis: Monitor patients for anaphylaxis and discontinue Zydelig.",
                    "Neutropenia: monitor blood counts."
                ],
                "contraindication": [
                    "History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis"
                ],
                "recognizingAuthority": {
                    "@type": "Organization",
                    "name": "U.S. Food and Drug Administration",
                    "alternateName": "FDA",
                    "url": "https://www.fda.gov/"
                }
            },
            {
                "@type": "Drug",
                "name": "ZYDELIG®",
                "offers": {
                    "@type": "Offer",
                    "price": "0",
                    "priceCurrency": "USD"
                },
                "activeIngredient": "idelalisib",
                "alternateName": "ZYDELIG® (idelalisib)",
                "description": "ZYDELIG is a PI3Kδ inhibitor indicated for Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab in patients for whom rituximab alone would be consider appropriate therapy due to other comorbidities.",
                "dosageForm": "tablet",
                "administrationRoute": "oral",
                "doseSchedule": [
                    {
                        "@type": "DoseSchedule",
                        "frequency": "twice-daily",
                        "doseUnit": [
                            "150 mg",
                            "100 mg"
                        ],
                        "targetPopulation": [
                            "adults",
                            "adults who have received at least two prior systemic therapies"
                        ]
                    }
                ],
                "pregnancyWarning": "Embryo-fetal toxicity: Zydelig may cause fetal harm. Advise women of potential risk to a fetus and to avoid pregnancy while taking Zydelig.",
                "breastfeedingWarning": "Lactation: Advise women not to breastfeed",
                "warning": [
                    "WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC,SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, and INTESTINAL PERFORATION See full prescribing information for complete boxed warning",
                    "Fatal and/or serious hepatotoxicity occurred in 16% to 18% of Zydelig-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Zydelig.",
                    "Fatal and/or serious and severe diarrhea or colitis occurred in 14% to 20% of Zydelig-treated patients. Monitor for the development of severe diarrhea or colitis. Interrupt and then reduce or discontinue Zydelig.",
                    "Fatal and/or serious pneumonitis occurred in 4% of Zydeligtreated patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt or discontinue Zydelig",
                    "Fatal and/or serious infections occurred in 21% to 48% of Zydelig-treated patients. Monitor for signs and symptoms of infection. Interrupt Zydelig if infection is suspected.",
                    "Fatal and serious intestinal perforation can occur in Zydeligtreated patients across clinical trials. Discontinue Zydelig if intestinal perforation is suspected."
                ],
                "image": {
                    "@type": "ImageObject",
                    "name": "ZYDELIG®(idelalisib)logo",
                    "contentUrl": "https://www.zydelig.com/Content/images/logo.png"
                },
                "manufacturer": {
                    "@type": "Organization",
                    "name": "Gilead",
                    "logo": "https://www.zydelig.com/Content/images/GILEAD-logo.png"
                }
            }
        ]
    },
    {
        "@context": "https://schema.org",
        "@type": "WebSite",
        "url": "https://www.zydelig.com/",
        "potentialAction": {
            "@type": "SearchAction",
            "target": "https://www.zydelig.com/search-result?q={search_term_string}",
            "query-input": "required name=search_term_string"
        }
    }
]

{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://health-lifesci.schema.org/Patient",
    "specialty": "https://health-lifesci.schema.org/Oncologic",
    "url": "https://www.zydelig.com/about-zydelig",
    "headline": "Learn More About ZYDELIG® (idelalisib) | Treatment for CLL",
    "description": "Find out about ZYDELIG® (idelalisib), a medication used in the treatment of relapsed chronic lymphocytic leukemia (CLL) and learn more about how it may work.",
    "mainContentOfPage": {
        "@type": "WebPageElement",
        "potentialAction": [
            {
                "@type": "Action",
                "name": "View the safety profile",
                "url": "https://www.zydelig.com/side-effects/common-side-effects"
            },
            {
                "@type": "Action",
                "name": "Learn More",
                "description": "Understand your ZYDELIG dose and how to take your medication exactly as prescribed",
                "url": "https://www.zydelig.com/taking-zydelig"
            }
        ],
        "text": "What sets ZYDELIG apart? It's an oral medication: ZYDELIG is an oral medication used to treat relapsed relapsed chronic lymphocytic leukemia (CLL). It works differently: ZYDELIG was approved in 2014 and works by blocking PI3K delta, a protein that contributes to CLL."
    },
    "about": [
        {
            "@type": "MedicalCondition",
            "name": [
                "Relapsed chronic lymphocytic leukemia (CLL)"
            ]
        },
        {
            "@type": "MedicalTherapy",
            "guideline": [
                "Adult starting dose: One 150 mg tablet twice daily, swallowed whole with or without food. Continue treatment until disease progression or unacceptable toxicity. The safe dosing regimen for patients who require treatment longer than several months is unknown.",
                "Dose modification: Consult the ZYDELIG full Prescribing Information for dose modification and monitoring recommendations for the following specific toxicities: pneumonitis, ALT/AST elevations, bilirubin elevations, diarrhea, neutropenia, thrombocytopenia, and infections. For other severe or life-threatening toxicities, withhold ZYDELIG until toxicity is resolved and reduce the dose to 100 mg twice daily upon resuming treatment. If severe or life-threatening toxicities recur upon rechallenge, ZYDELIG should be permanently discontinued.",
                "CYP3A inducers: Avoid coadministration with strong CYP3A inducers.",
                "CYP3A inhibitors: Avoid coadministration with strong CYP3A inhibitors. If unable to use alternative drugs, monitor patients more frequently for ZYDELIG adverse reactions.",
                "CYP3A substrates: Avoid coadministration with sensitive CYP3A substrates."
            ],
            "adverseOutcome": "The most common adverse reactions (incidence ≥20%) in patients treated with Zydelig in the monotherapy trial are diarrhea, fatigue nausea, cough, pyrexia, abdominal pain, pneumonia, and rash.The most common adverse reactions (incidence ≥30%) in patients treated with Zydelig in combination trials are diarrhea, pneumonia,pyrexia, fatigue, rash, cough, and nausea.Common laboratory abnormalities include neutropenia, ALT elevations and AST elevations.",
            "seriousAdverseOutcome": [
                "Severe cutaneous reactions: Monitor patients for the development of severe cutaneous reactions and discontinue Zydelig.",
                "Anaphylaxis: Monitor patients for anaphylaxis and discontinue Zydelig.",
                "Neutropenia: monitor blood counts."
            ],
            "contraindication": [
                "History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis"
            ],
            "recognizingAuthority": {
                "@type": "Organization",
                "name": "U.S. Food and Drug Administration",
                "alternateName": "FDA",
                "url": "https://www.fda.gov/"
            }
        },
        {
            "@type": "Drug",
            "name": "ZYDELIG®",
            "offers": {
                "@type": "Offer",
                "price": "0",
                "priceCurrency": "USD"
            },
            "activeIngredient": "idelalisib",
            "alternateName": "ZYDELIG® (idelalisib)",
            "dosageForm": "tablet",
            "administrationRoute": "oral",
            "doseSchedule": [
                {
                    "@type": "DoseSchedule",
                    "frequency": "twice-daily",
                    "doseUnit": [
                        "150 mg",
                        "100 mg"
                    ],
                    "targetPopulation": [
                        "adults",
                        "adults who have received at least two prior systemic therapies"
                    ]
                }
            ],
            "pregnancyWarning": "Embryo-fetal toxicity: Zydelig may cause fetal harm. Advise women of potential risk to a fetus and to avoid pregnancy while taking Zydelig.",
            "breastfeedingWarning": "Lactation: Advise women not to breastfeed",
            "warning": [
                "WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC,SEVERE DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, and INTESTINAL PERFORATION See full prescribing information for complete boxed warning",
                "Fatal and/or serious hepatotoxicity occurred in 16% to 18% of Zydelig-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Zydelig.",
                "Fatal and/or serious and severe diarrhea or colitis occurred in 14% to 20% of Zydelig-treated patients. Monitor for the development of severe diarrhea or colitis. Interrupt and then reduce or discontinue Zydelig.",
                "Fatal and/or serious pneumonitis occurred in 4% of Zydeligtreated patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt or discontinue Zydelig",
                "Fatal and/or serious infections occurred in 21% to 48% of Zydelig-treated patients. Monitor for signs and symptoms of infection. Interrupt Zydelig if infection is suspected.",
                "Fatal and serious intestinal perforation can occur in Zydeligtreated patients across clinical trials. Discontinue Zydelig if intestinal perforation is suspected."
            ],
            "image": {
                "@type": "ImageObject",
                "name": "ZYDELIG®(idelalisib)logo",
                "contentUrl": "https://www.zydelig.com/Content/images/logo.png"
            },
            "manufacturer": {
                "@type": "Organization",
                "name": "Gilead",
                "logo": "https://www.zydelig.com/Content/images/GILEAD-logo.png"
            }
        }
    ]
}